Archive | December, 2019

3 Days Until RESI SF Partnering Launches!

5 Dec

By Bryanna Allison, Business Development Manager, LSN

Mark your calendar for Monday, December 9th. The partnering portal for RESI San Francisco will launch around 11am EST! First things first, are you registered for the conference? You will only have access to the partnering portal after you have registered. If you haven’t, please don’t wait!  It’s an advantage to be in partnering at launch in order to get the first touch out to investors.

The RESI Conference was designed as a partnering conference to ensure every one of your meetings is worthwhile, based on a strong fit between company and investor.  RESI Partnering provides fully tagged profiles of all the investors attending, based on interview conducted by LSN’s Investor Research team.  Our RESI Premier Partnering attendees can also see in depth profiles on investor technology interests and get direct contact with investors.  Would you like to meet with these investors, and more?  Sign up for RESI now.

CONFIRMED RESI SAN FRANCISCO INVESTORS AND STRATEGIC PARTNERS

As of Dec. 3rd, 2019

 

 

Last Call for RESI SF Innovation Challenge Applications!

5 Dec

By Karen Deyo, Senior Investor Research Analyst, LSN

The deadline for applying to the RESI SF Innovation Challenge is tomorrow, Friday, Dec. 6th, and this is the last call for companies to submit their applications for consideration. The Innovation Challenge is a unique competition, where companies are selected using criteria such as innovativeness, stage of development, market size and opportunity and competitive landscape. The top companies, identified for their ‘investability,’ present posters in the exhibit hall on the day of the conference, competing for ‘investments’ of ‘RESI Cash’ from attendees to win prizes.

Participation in the Innovation Challenge can benefit finalists in many ways, including the increased exposure gained by the feature in the LSN Newsletter, the printed RESI Program Guide, as well as onsite signage at RESI. In addition, companies that actively seek ‘investments’ from attendees find that this can lead to many productive ad hoc meetings, furthering their fundraising campaigns in sometimes unexpected ways.

Click here to apply to the Innovation Challenge – good luck!

 

Artificial Intelligence is the Future of Healthcare

5 Dec

By Lucy Parkinson, VP of Investor Research, LSN

At LSN we speak to investors day in, day out, about what technologies they are seeking for their future portfolios. Many are now looking for artificial intelligence (AI) solutions across all of the sectors that LSN covers – drugs, devices, diagnostics and digital health. Investors are interested in the power of AI: from drug discovery tools to data analytics, from genomics to clinical decision support, and also including image analysis and patient monitoring, to name a few.

It’s clear that there is an emerging interest in bringing these fields together. LSN has already used RESI to dip our toes in the water of AI, with regular panels on AI in Healthcare; at RESI Taipei, Professor Jack Li delivered a presentation on the future AI landscape of healthcare, which highlighted the role AI can play in lowering the costs of future care delivery. We’ve found these topics have resonated with both investors and entrepreneurs in early stage life sciences. There are many avenues for adding AI as an extra dimension to new technologies, such as using AI to analyze data from new drugs or devices.

RESI San Francisco will include two investor panels specifically devoted to artificial intelligence: the broad AI in Healthcare panel, and a more focused panel on AI in Pathology and Imaging, a key sector for the advancement of healthcare AI.  AI is also a key topic in other panels such as Oncology Innovation and Investing in Life Science Tools.  With so much innovation happening in this space, RESI hopes to help investors and entrepreneurs who are focused on healthcare AI connect with each other.

LSN is planning further dedicated content in this space; look out for the launch of 4D Meets AI soon.

Global Family Office BioForum to Sponsor RESI’s 2020 Events Worldwide

5 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

We are delighted to announce that the Global Family Office Bioforum (GFOB) will be RESI’s title sponsor for 2020.

The Global Family Office BioForum (GFOB) is the leading alliance of international Family Offices focused on healthcare/life science which meets quarterly in 18 cities in the US, Europe and Asia.  GFOB also has a joint partnership with Life Science Nation and the RESI conference Series. These initiatives aim to assist the earliest stage life sciences companies by sourcing seed capital and management talent.

 

Hot Investor Mandate: Silicon Valley VC Invests in Therapeutics, Diagnostics, Tools and Devices

5 Dec

A venture capital firm with investment teams in Silicon Valley (headquarters) and Europe is currently investing out of their third $355M fund, and looks to invest in early-stage life science companies crossing all sectors. The firm focuses on Seed, Series A and Series B investments. Investment is in the form of equity with the firm making roughly 3-5 new investments per year. The firm typically invests $500K – $5M per round (depending on the stage and needs of the company), and generally invests $10-$15M throughout the life of a company. The firm is very comfortable leading investment rounds, and focuses on companies in the US and Europe.

In the life sciences, the firm is looking for new investment opportunities in the therapeutics, diagnostics, tools and medical device sectors. The firm is opportunistic in terms of sub-sectors and indications. the firm is only interested in preclinical/Phase I, early-stage technology. The firm looks for companies with proprietary technologies that allow them to address unmet needs in a unique and compelling manner. The firm is not interested in healthcare IT, healthcare services or software companies.

The firm in privately-held companies with passionate founders and/or a strong management team. The firm looks to take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Equity Firm Invests Globally in Surgical Innovations

5 Dec

A private equity firm founded in 2014 and is based in New York and Montreal. The firm manages the a fund that provides equity and equity-like investments in high growth companies in healthcare technology verticals, with a focus on surgery. The size of investments generally fall under the range of $2-5 M per company, and the firm seeks to make 2-3 investments per year. The firm looks globally with a strong focus in North America.

The firm is interested in highly innovative medical and surgical device companies, healthcare IT, healthcare services. The firm will not consider products in pharma or biotech industries. Medical device products should be patented and on the cusp of FDA clearance. The firm will support all classes of medical devices including 510k and PMA regulatory pathways. Healthcare IT companies are expected to demonstrate market traction prior to investment.

The firm seeks to work with companies with an experienced, motivated management team. The firm can act as the lead investor in all financing rounds, and requires a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based Pharma Looks for Early Stage Partnerships in CNS, Immunology, Liver Disease and More

5 Dec

A pharmaceutical company based in Asia is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in movement disorders, CNS, liver disease and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in early/late non-clinical development stage as well as in early clinical development stage.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →